L1 cell adhesion molecule: A novel potential biomarker for IE patients at high risk of embolism and adverse events.

IF 2.7 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Hellenic Journal of Cardiology Pub Date : 2025-03-07 DOI:10.1016/j.hjc.2025.03.001

Jian Hou, Dayu Wang, Tingfeng Chen, Zhen Liu, Ruibing Wei, Cuiping Wang, Suiqing Huang

{"title":"L1 cell adhesion molecule: A novel potential biomarker for IE patients at high risk of embolism and adverse events.","authors":"Jian Hou, Dayu Wang, Tingfeng Chen, Zhen Liu, Ruibing Wei, Cuiping Wang, Suiqing Huang","doi":"10.1016/j.hjc.2025.03.001","DOIUrl":null,"url":null,"abstract":"Aims: Despite advancements in medical and surgical therapies, infectious endocarditis (IE) remains life-threatening due to its complications. This study aimed to evaluate the clinical value and function of L1 cell adhesion molecule (L1CAM) in IE.Methods: A prospective observational study included 94 IE patients (40 with embolic events [EEs], 54 without; 38 with adverse events, 56 without) and 25 healthy controls. Adverse events were defined as death or poorly controlled conditions requiring surgery. Plasma L1CAM levels were measured using enzyme-linked immunosorbent assays. Logistic regression and receiver operating characteristic (ROC) curves assessed L1CAM's predictive value for EEs and adverse events.Results: L1CAM levels were higher in IE patients than in healthy controls (47.60 ± 10.86 vs. 94.80 ± 68.84 pg/mL, P = 0.008). Among IE patients, those with EEs or adverse events had significantly elevated L1CAM levels (EEs: 127.70 ± 78.20 vs. 70.45 ± 48.96 pg/mL; adverse events: 129.00 ± 79.79 vs. 71.59 ± 48.73 pg/mL, both P < 0.001). Multivariate analysis showed L1CAM as an independent predictor for EEs (OR = 1.02; 95% CI = 1.01-1.04; P = 0.001) and adverse events (OR = 1.01; 95% CI = 1.00-1.02; P = 0.003). AUCs were 0.7273 and 0.7119 for EEs and adverse events, respectively. L1CAM correlated positively with WBC (P = 0.028, r = 0.225) and CRP levels (P = 0.025, r = 0.231).Conclusions: L1CAM may serve as a biomarker for embolism and adverse events in IE patients.","PeriodicalId":55062,"journal":{"name":"Hellenic Journal of Cardiology","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic Journal of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.hjc.2025.03.001","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Despite advancements in medical and surgical therapies, infectious endocarditis (IE) remains life-threatening due to its complications. This study aimed to evaluate the clinical value and function of L1 cell adhesion molecule (L1CAM) in IE.

Methods: A prospective observational study included 94 IE patients (40 with embolic events [EEs], 54 without; 38 with adverse events, 56 without) and 25 healthy controls. Adverse events were defined as death or poorly controlled conditions requiring surgery. Plasma L1CAM levels were measured using enzyme-linked immunosorbent assays. Logistic regression and receiver operating characteristic (ROC) curves assessed L1CAM's predictive value for EEs and adverse events.

Results: L1CAM levels were higher in IE patients than in healthy controls (47.60 ± 10.86 vs. 94.80 ± 68.84 pg/mL, P = 0.008). Among IE patients, those with EEs or adverse events had significantly elevated L1CAM levels (EEs: 127.70 ± 78.20 vs. 70.45 ± 48.96 pg/mL; adverse events: 129.00 ± 79.79 vs. 71.59 ± 48.73 pg/mL, both P < 0.001). Multivariate analysis showed L1CAM as an independent predictor for EEs (OR = 1.02; 95% CI = 1.01-1.04; P = 0.001) and adverse events (OR = 1.01; 95% CI = 1.00-1.02; P = 0.003). AUCs were 0.7273 and 0.7119 for EEs and adverse events, respectively. L1CAM correlated positively with WBC (P = 0.028, r = 0.225) and CRP levels (P = 0.025, r = 0.231).

Conclusions: L1CAM may serve as a biomarker for embolism and adverse events in IE patients.

查看原文本刊更多论文

L1细胞粘附分子：一种新的潜在生物标志物，可用于高风险栓塞和不良事件的IE患者。

目的：尽管医学和外科治疗取得了进步，但感染性心内膜炎（IE）仍因其并发症而危及生命。本研究旨在探讨L1细胞粘附分子（L1 cell adhesion molecule, L1CAM）在IE中的临床价值和功能。方法：一项前瞻性观察研究纳入了94例IE患者(40例有栓塞事件[EEs]， 54例无；38例有不良事件，56例没有)和25例健康对照。不良事件被定义为死亡或需要手术的控制不良情况。采用酶联免疫吸附法测定血浆L1CAM水平。Logistic回归和受试者工作特征（ROC）曲线评估L1CAM对EEs和不良事件的预测价值。结果：IE患者L1CAM水平高于健康对照组（47.60±10.86∶94.80±68.84 pg/mL, P = 0.008）。在IE患者中，有EEs或不良事件的患者L1CAM水平显著升高(EEs: 127.70±78.20 vs 70.45±48.96 pg/mL；不良事件：129.00±79.79 vs 71.59±48.73 pg/mL， P均< 0.001)。多因素分析显示L1CAM是EEs的独立预测因子(OR = 1.02；95% ci = 1.01-1.04；P = 0.001)和不良事件(OR = 1.01；95% ci = 1.00-1.02；P = 0.003)。EEs和不良事件的auc分别为0.7273和0.7119。L1CAM与WBC （P = 0.028, r = 0.225）、CRP （P = 0.025, r = 0.231）呈正相关。结论：L1CAM可作为IE患者栓塞和不良事件的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hellenic Journal of Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

4.90

自引率

7.30%

发文量

审稿时长

56 days

期刊介绍： The Hellenic Journal of Cardiology (International Edition, ISSN 1109-9666) is the official journal of the Hellenic Society of Cardiology and aims to publish high-quality articles on all aspects of cardiovascular medicine. A primary goal is to publish in each issue a number of original articles related to clinical and basic research. Many of these will be accompanied by invited editorial comments. Hot topics, such as molecular cardiology, and innovative cardiac imaging and electrophysiological mapping techniques, will appear frequently in the journal in the form of invited expert articles or special reports. The Editorial Committee also attaches great importance to subjects related to continuing medical education, the implementation of guidelines and cost effectiveness in cardiology.